Ono Pharmaceutical has acquired exclusive development and commercialisation rights in Japan to Concordia Pharmaceuticals' direct Ras inhibitor salirasib, which it will develop initially for pancreatic cancer.
The Japanese firm will pay undisclosed ...
Roche's Japanese subsidiary, Chugai , has made an approval filing for Xeloda (capecitabine) for the treatment of advanced or refractory gastric cancer in patients who are not candidates for curative surgery.
The submission follows a formal request ...
The Japanese government is to provide a multi-million dollar subsidy to the country's largest pharma company for the development of cell cultured vaccines for pandemic influenza.
Following an application for the support, Takeda has been notified ...
The US FDA has extended by three months the NDA review period for Eisai 's anticancer product eribulin mesylate. The agency now expects to complete its priority review for use in locally advanced or metastatic breast cancer on or before 30 ...
Kyowa Hakko Kirin has withdrawn an approval filing in Japan for a sublingual tablet formulation of fentanyl citrate for the treatment of breakthrough pain in cancer patients.
The opioid agonist, coded KW-2246 by the Japanese firm, is licensed in ...
